Acadia Pharmaceuticals (ACAD) Accumulated Expenses (2010 - 2026)

Acadia Pharmaceuticals' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $293.3 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 1060.9% year-over-year to $293.3 million; the TTM figure through Mar 2026 stood at $293.3 million (up 1060.9% YoY), while the FY2025 annual figure was $266.2 million, down 29.7% from the prior year.
• Accumulated Expenses was $293.3 million for Q1 2026 at Acadia Pharmaceuticals, up from $266.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $378.7 million in Q4 2024 to a low of $10.9 million in Q3 2025.
• Historically, Accumulated Expenses has averaged $157.9 million across 5 years, with a median of $112.9 million in 2022.
• Biggest YoY gain for Accumulated Expenses was 1090.01% in 2025; the steepest drop was 96.65% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $112.9 million in 2022, then soared by 109.69% to $236.7 million in 2023, then jumped by 59.97% to $378.7 million in 2024, then decreased by 29.7% to $266.2 million in 2025, then grew by 10.17% to $293.3 million in 2026.
• The last three Accumulated Expenses figures came in at $293.3 million (Q1 2026), $266.2 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.